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cumplement system is part of the innate immune system.
and is foUnd in ill m IL hi its as ss II is in in InLIL ismn_!
iL number of invertebrates The complement s’ystem contains
over thirty proteins that are involved in three different acti\ aUon
cascades and one terminal pathway, as well as a number of proteins
involved in regulating complement activation. One complement
component. C3. plays important roles in two of the amplification
cascades. and plays the central role in the third, the alternative path—
ss a AP. in the AP. C3 undergoes a spontaneous contorniational
change that exposes multiple protein binding sites and results in the
cleavage of a high—energy thiocster linkage found onl in C3. C4.
the serum protease inhibitor —2—macroglobulin. and two recently
discovered proteins. CPANMD8 and CDl09”. The ictivated CS.
called iC3 or C3( H,O) is able to hind another complement protein.
factor B, which can he cleaved by another complement protein, fac
tor D, to yield the AP C3/C5 convertase. iC3.Bh. This convertase
can activate more C3 molecules by cleaving off the C3a peptide
from the activated C3. called C3h. CSb can then hind other factor
B molecules to form more C31C5 eonvertases. B binding a second
C3h molecule, a CS convertase can more efticientlv cleave C5 into
theanaphvlatoxin C5a. andthe active form. C5h. which hinds C0—C9
to form the membrane attack complex in the terminal complement
pathv;ay for review. secj.
Complement activation provides the body tirst line of defense
against bacterial and viral disease. as complement can either target
“non—self” cells forphagocytosis orcause their lysis. However, there
are certain diseases, and certain situations, where complement activa
tion is actually responsible for a majority of the disease symptoms. or
resulting datriage. Forexample. the fact that complement activit\ is
seen in the joint fluid of pmtments sLiffering from rheumatoid arthritis
suggests the mn olvement of complement in this disease. Coinple
ment activation has also been implicated in other immune—mediated
diseases, such as Nivasthenia gravis and various forms of lupus I for
res iess. see . Actl\ ation of complement has also been seen to he a
cause of the tissue damage in mn ocardial infarctions and repcrftismon
injurieff. FinalE, complement i5 a majorcause of rejection of foreign
tissue (luring xenotransplantation procedures. For these reasons,
there has been a great deal of research on substances that are able
to inhibit the acli\ anon of complcmentH, with ses eral compounds
no in clinical trials. Examples of these therapies include antibodies
to complement proteins, complement proteins that are truncated to
alter their actis t. and small molecules or protease inhibitors that
prevent the act is amion of complement. One commonality anlaug
all these potential anti—complement drugs i5 thai the inhibit the
action of complement. We are 1105k examining an alternative means
of blocking complement action by depleting the complement in an
organism.
Cobra Venom Factor I CVF) is a protein found in the venom of
most elapid snakes. The protein has been extensivel studied,
and been shown to be an analog of complement C3 Sequencing of
CVF in our laboratory has shown that it is highly homologous to
C3 from many other species. with homology ranging from about
70ff in mammals to >90 homology to cobra C3 . Though the
mature protein has a structure similar to C3c. one of the breakdoss n
products of CS. functionall it most resembles CSh in that it is able
to bind factor B. which is then cleaved by factor D to form the CVF
containing CS/CS con\ ertase, CVF.Bha.
While functionally similar to C3h. CVF also shows some signiti—
cant differences. Convertases formed \yith either C3b or CVF are
inherently unstable, and will spontaneously dissociate to Bb plus
C3b (or CVF). However, the CVF-contamning convertse is far more
stable than the C3b containing enzyme. with a t, of approximately
7 hours vs. I .5 minutes°. The CVF-eontaining enzyme is also
not subject to regLilation and cleas age by factors H and I . In
addition, the CVF—containing cons ertase is able to cleave CS on
its own. ss hue the C3b-eontaining enIvme needs to have a second
C3h molecule covalentlv hound. Finally, lacking a thioester.
the CVF—containing entvnie remains in the fluid phase. ss bile the
C3b—containing convertase acts at the cell surface. The fact that
CVF is able to form a relatively stable convertase that is resistant
to the action of factors H amid I means that the addition of CVF to
serum results in complement depletion. Indeed, injection of CVF
into laboratory animals causes complement depletion of the animal
seer and references therein!. Compleument depletion by treatment
with CV F has been shov n to he useful for the treatment of mans
complement—mediated diseases in animal models I forres mess, see
In addition, it has been shown that (‘Vt——antibody conjugates can
be used for complement—mediated destruction of tumor cells.
Hoss es em. using CVF for complement depletion does has e two
major drawbacks . Since complement is the first line of defense
against inlection, complete complement depletion could leave the
patient susceptible to bacterial or viral infection. Secondly. CV F is
extremel\ immunogenic. CVF contains u-galactosyl residues at the
end of the carbohydrate chains which aie not found in mammalian
proteins. aud are hmghl\ Immunogenic in themsels es Secondl
CVI— is ouR about 50’ identical 70ff sinimlarm to maumutalian CS
protemn’. meauimme the structure itself ss ould he immunogenic.
In our laborator. sse are studs mug the str1mcturc/f unction relation
ships mu complement (‘S and CVF b u’mng site—directed mutaen
vsiS 10 mthui rcpl 0i I iomis of hum mu I ss ith homnolo,ous I Vt-
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sequences. ‘ to replace portions of C \ F tit hoinoioeon c )bra
(‘3 sequences. In doi no so. s e have prepared a number of human
C3/CVF hybrid proteins with novel properties. With one excep
tion, all the hybrid proteins described contain substitutions of CVF
sequences at the very C-terminus of the x-chain of human C3, and
contain CVF substitutions of varying sizes from approximately I 10
amino acid residues to 3 15 residues, comprising between 66f4 and
I of the protein. These hybrid proteins are named HC3- I 550,
HCS- l504, HC3- 14%. and FIC3-l 34, where the number is the
position of the beginnni of the C’\ F substitution tn the human
CS sequence. In the one exception. I 1C3- 1550;! 617. human C’S
Neqnences replace the C—terminal 46 antino acids of HCS— 1550.
Figure I shows a representation of the proteins used in this stnd\.
All of these h\ brid proteins sho\s ar\ I ng amounts of C\ F- like
behavior, in that they are able to bi itd factor B to form a CS/CS
convertase that is inherently more stable than the CSb-eontaining
convertase. The convertase formed by the hybrid proteins is, in all
eases. able to cleave C3. though not CS, and, surprisingh. all hut
HC3— 1550/1617 are able to deplete complement in human serum,
though less efficiently than CVF. The relative efficiencies of the
hybrid pre teins arv between 0.3 and 20 .Two proteins (HC3- I 34
and HC3 1 496 are actual lv able to l irm eonvertases that are more
aett e in cleaving CS than the C\ F-eontaniing convertase. Thesc
data are suniinari,ed ni Fiy’nre 2.
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Figure 1,— Map of portions of human C3 replaced with CVF sequences,
The (ore s The port 3”S OF hjri’dP C3 vpe reota5e h cob a sero’” aco “acbed sac cs C3a t5e “ach’ a ox” ocr’ on of C e’”c —d be C3 a ce’i e no
to the active torm called C3b. C3dg is the part of the mature C3 protein removed in the proteolytic conversion ot C3o to C3c.
A
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Figure 2 C plement depletion o uman serum caus y ddition of hybrid p ot ins
The amounts o hybrid roters shown , e e added to 10 p1 of bumar se. and ncubateo at 37 C three 5oUrs Affe .sard , , actn , as dIIfed ‘foid and 10 fr o :he
diluted reaction added to 30 p10 senstzeo sneep e’y’hrocyfes 5x 10 4i mh and Ir’cubated to’ 3’D “flutes at 37 C Reactm’s n,e’ stooped Or’ e addtpr F 1 ri’ ce-cold bPer
eryti. ocytes pa leted by rentr fugaton a”d oleased henog ohm rneas, d oho:oirer cas The cr- srioss :ne eav,’e a’nocit o’np emrent a”: ,ty oele’o on ft’e se’jn,
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These hybrid human C3/CVF proteins show great promise br use in complement
depletion. We are continuing to exarni ne the properties of these and other hLimail C31
CVF hybrid proteins in which substitutions are made either at the very C—terminus or
in other portions of the protein. Our long—term goal is to create novel human C3—like
proteins ith CVF—like properties, and to detine portIons oIC3 that aie required for its
bunetion.
For more inforniation on the Cancer Research Center of Has an. please visit our
\s ebsite at www.ereh.org.
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Classified Notices
To place a classified nottCe:
HMAmembers.—Asabenefitof membership, HMA
members may place a Complimentary one-time clas
sified ad in HMJ as space is available.
Nonmembers.—Rates are S1.50 a word with a
minimum of 20 words or S30. Not commissionable.
For more information call (808) 536-7702.
Office Space & Support Services
ALA MOANA BLDG— PHYSICIAN WANTED to share
space and support services, Interest in physical rehab.
preferred. We have unique time-share arrangements starting
at one halt-day per week. Run your practice with no fixed
overhead. Contact Dr. Speers, REHABILITATION ASSOCI
ATES, 955-7244.
Physician Wanted
PRIMARY CARE PHYSICIAN
— HALF-TIME. University
Health Services Manoa, call Lily Ning MD at 808-856-8965
for information.
Kuakini Physicians Tower
For Sale (Leasehold)
Medical Office Condo
Units available from 652 to 1,527 sq. ft.
Prices starting at $126500
Design your ideal office space
or
Lease a finished office space
Lease Rents from $2.40 psf
+ utilities and parking
Craig Nakamura (PB)
Commercial Properties Of Honolulu
591 -8755
Peter M. Lee (R)
Marcus & Associates, Inc.
839-7446r rL’-mZ,c
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